The first implication that HGF might be a therapeutic agent for the treatment of patients with ALS was obtained by transgenic over-expression of HGF in the nervous system in mouse model for ALS with mutant SOD1 [143,144]. The gene discussed is HGF; the disease is amyotrophic lateral sclerosis.